Project Details
| Status | Active |
|---|---|
| Effective start/end date | 23/02/23 → 22/02/28 |
A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-1)
- Sundram, Suresh (Primary Chief Investigator (PCI))
Project: Research